Vivus on track as it files anti-obesity drug with US FDA
This article was originally published in Scrip
Vivus has submitted its anti-obesity drug Qnexa (phentermine plus topiramate) for review with the US FDA. The move comes only a week after Arena Pharmaceuticals filed its fat-fighting drug lorcaserin with the agency (scripnews.com, December 23rd, 2009). A third candidate, Orexigen's Contrave (bupropion plus naltrexone), is due to be filed in the first half of next year.